. Author manuscript; available in PMC: 2016 Jan 31.

Published in final edited form as: Pediatr Clin North Am. 2015 Feb;62(1):139–165. doi: 10.1016/j.pcl.2014.09.010

Table 3.

Standard treatment options for low-stage non-Hodgkin lymphoma

Disease	Treatment Options	Outcomes
BL or DLBCL (completely resected)	BFM-90/95 (R1): 2 cycles of chemotherapy¹⁰	EFS >95%
BL or DLBCL (completely resected)	COG-C5961 (FAB/LMB-96) (group A): 2 cycles of chemotherapy¹¹⁴	EFS >95%

BL or DLBCL (nonresected stage I/II)	BFM-95 (R2): Prephase + 4 cycles of chemotherapy (4-h methotrexate infusion)¹⁰	EFS 95%
BL or DLBCL (nonresected stage I/II)	COG-C5961 (FAB/LMB-96) (group B): prephase + 4 cycles of chemotherapy (reduced-intensity arm)³⁰	EFS 98%

ALCL	POG-8314/POG-8719: 3 cycles of CHOP²⁶	EFS 88% for DLBCL and ALCL (5 y)
	BFM-90: prephase + 3 cycles of chemotherapy (only for completely resected disease)¹¹⁵	90% EFS
	ALCL99: prephase + 6 cycles of chemotherapy (for disease not completely resected)¹¹⁶	Completely resected patients: 100% EFS Patients without complete resection: EFS 81% (3 y)

Abbreviations: BFM, Berlin-Frankfurt-Munster; FAB, French-American-British.